Persistence in muscle of an adenoviral vector that lacks all viral genes.

Genetic correction of inherited muscle diseases, such as Duchenne muscular dystrophy, will require long term expression of the recombinant protein following gene transfer. We have shown previously that a new adenoviral vector that lacks all viral genes expressed both full-length dystrophin and beta-galactosidase in mdx (dystrophin-deficient) mouse muscle. We observed a significant histologic improvement of vector-transduced mdx muscle before the eventual loss of vector-encoded transgene expression. In this study, we investigated whether an immunological response against vector-encoded beta-galactosidase contributed to the loss of vector expression and affected vector persistence in muscle. Intramuscular vector injection in control normal mice resulted in an early and complete loss of beta-galactosidase expression accompanied by predominantly CD4+ and CD8+ lymphocytic infiltration and a significant loss of vector DNA. In contrast, intramuscular vector injection in lacZ transgenic mice resulted in persistent expression of beta-galactosidase for at least 84 days with no evidence of inflammation or significant loss of vector DNA. Our studies demonstrate that, in the absence of an immune response induced by beta-galactosidase expression, an adenoviral vector lacking all viral genes is stably maintained in muscle.

[1]  K. Campbell,et al.  In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. , 1996, Gene therapy.

[2]  J. Chamberlain,et al.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. , 1996, Human molecular genetics.

[3]  J. Mandel,et al.  Adenovirus as an expression vector in muscle cells in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Perricaudet,et al.  Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.

[5]  M. Perricaudet,et al.  Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[8]  J. Wilson,et al.  Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. , 1996, Virology.

[9]  G. Splitter,et al.  Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. , 1995, Human gene therapy.

[10]  R. Balice-Gordon,et al.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. , 1996, Human gene therapy.

[11]  P. Briand,et al.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice , 1993, Nature.

[12]  G. Cossu,et al.  Myosin light chain 3F regulatory sequences confer regionalized cardiac and skeletal muscle expression in transgenic mice , 1995, The Journal of cell biology.

[13]  D. Coen,et al.  Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants , 1990, Journal of virology.

[14]  K. Berkner Development of adenovirus vectors for the expression of heterologous genes. , 1988, BioTechniques.

[15]  J. Leiden,et al.  Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Hodges,et al.  The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle , 1988, Nature.

[17]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[18]  C. Caskey,et al.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Naviaux,et al.  Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Graham,et al.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Leiden,et al.  Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.

[22]  Hanns Lochmüller,et al.  Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. , 1995, Biochemical and biophysical research communications.

[23]  J. Johnson,et al.  Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts , 1986, Molecular and cellular biology.

[24]  M. Fardeau,et al.  Expression of a recombinant dystrophin in mdx mice using adenovirus vector , 1994, Neuromuscular Disorders.

[25]  C. Caskey,et al.  Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. , 1995, Human gene therapy.

[26]  J. Wilson,et al.  Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.

[27]  Hanns Lochmüller,et al.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. , 1996, Human gene therapy.

[28]  C. Caskey,et al.  Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. , 1989, Nucleic acids research.